No annual revenue total was found in Braveheart Bio, Inc.'s SEC filings.
Braveheart Bio, Inc. (BRVE) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $122.8 million in cash and investments and $575,000 in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$122.26M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BRVE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2131524
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 8, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 7, 2026 | Aug 5, 2026 |
All 46 Braveheart Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.